187 related articles for article (PubMed ID: 37980571)
21. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA; Taddei T; Jain D; Zhang X
Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
[TBL] [Abstract][Full Text] [Related]
22. Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Do WL; Wang L; Forgues M; Liu J; Rabibhadana S; Pupacdi B; Zhao Y; Gholian H; Bhudhisawasdi V; Pairojkul C; Sukeepaisarnjaroen W; Pugkhem A; Luvira V; Lertprasertsuke N; Chotirosniramit A; Auewarakul CU; Ungtrakul T; Sricharunrat T; Sangrajrang S; Phornphutkul K; Budhu A; Harris CC; Mahidol C; Ruchirawat M; Wang XW
Cell Rep Med; 2023 Dec; 4(12):101328. PubMed ID: 38118412
[TBL] [Abstract][Full Text] [Related]
23. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
Makino K; Ishii T; Takeda H; Saito Y; Fujiwara Y; Fujimoto M; Ito T; Wakama S; Kumagai K; Munekage F; Horie H; Tomofuji K; Oshima Y; Uebayashi EY; Kawai T; Ogiso S; Fukumitsu K; Takai A; Seno H; Hatano E
J Pathol; 2024 May; 263(1):32-46. PubMed ID: 38362598
[TBL] [Abstract][Full Text] [Related]
24. Treating Hepatobiliary Cancers: The Oncology Way.
Galle PR
Dig Dis; 2017; 35(4):384-386. PubMed ID: 28468016
[TBL] [Abstract][Full Text] [Related]
25. N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
Gerber TS; Ridder DA; Goeppert B; Brobeil A; Stenzel P; Zimmer S; Jäkel J; Metzig MO; Schwab R; Martin SZ; Kiss A; Bergmann F; Schirmacher P; Galle PR; Lang H; Roth W; Straub BK
Int J Cancer; 2024 May; 154(10):1857-1868. PubMed ID: 38212892
[TBL] [Abstract][Full Text] [Related]
26. Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas.
Kikuchi AT; Umetsu S; Joseph N; Kakar S
Am J Surg Pathol; 2023 Nov; 47(11):1207-1218. PubMed ID: 37661782
[TBL] [Abstract][Full Text] [Related]
27. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.
Jeon Y; Kwon SM; Rhee H; Yoo JE; Chung T; Woo HG; Park YN
Hepatology; 2023 Jan; 77(1):92-108. PubMed ID: 35124821
[TBL] [Abstract][Full Text] [Related]
28. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
Nguyen Canh H; Takahashi K; Yamamura M; Li Z; Sato Y; Yoshimura K; Kozaka K; Tanaka M; Nakanuma Y; Harada K
Histopathology; 2021 Nov; 79(5):731-750. PubMed ID: 34018212
[TBL] [Abstract][Full Text] [Related]
29. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract][Full Text] [Related]
31. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
33. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances.
Li D; Lin S; Hong J; Ho M
Adv Cancer Res; 2022; 156():415-449. PubMed ID: 35961708
[TBL] [Abstract][Full Text] [Related]
35. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Ma L; Hernandez MO; Zhao Y; Mehta M; Tran B; Kelly M; Rae Z; Hernandez JM; Davis JL; Martin SP; Kleiner DE; Hewitt SM; Ylaya K; Wood BJ; Greten TF; Wang XW
Cancer Cell; 2019 Oct; 36(4):418-430.e6. PubMed ID: 31588021
[TBL] [Abstract][Full Text] [Related]
36. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
37. Impact of socio-economic environment on incidence of primary liver cancer in France between 2006 and 2016.
Comoz B; Ollivier-Hourmand I; Bouvier AM; Nousbaum JB; Nguyen TTN; Launoy G; Bouvier V; Bryere J
Liver Int; 2024 Feb; 44(2):446-453. PubMed ID: 38010978
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
39. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma.
Shetty AS; Fowler KJ; Brunt EM; Agarwal S; Narra VR; Menias CO
Abdom Imaging; 2014 Apr; 39(2):310-22. PubMed ID: 24407728
[TBL] [Abstract][Full Text] [Related]
40. Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
Mahmoudi S; Bernatz S; Althoff FC; Koch V; Grünewald LD; Scholtz JE; Walter D; Zeuzem S; Wild PJ; Vogl TJ; Kinzler MN
Eur J Radiol; 2022 Nov; 156():110556. PubMed ID: 36270195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
